|
Market Closed -
Bombay S.E.
06:02:27 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 561.90 INR | +2.42% |
|
-0.15% | +28.14% |
| 08-14 | Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
| 05-30 | Coral Laboratories Limited Recommends Final Dividend for the Financial Year 2025-2026 | CI |
Sales 2026 by Business Segment
Sales 2026 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical Formulations | 756M | 781M | 837M | 1.15B | 859M | |||||
Total Assets | 1.9B | 1.74B | 2.06B | 2.29B | 2.41B | |||||
Interest Expense | -1.41M | -3.38M | -2K | -976K | -1.71M | |||||
Income Tax Expense | 28.1M | 17.81M | 49.43M | 83.15M | 67.34M | |||||
CAPEX | -55.48M | -19.45M | -9.91M | -29.45M | -235M | |||||
EBT | 119M | 82.26M | 207M | 325M | 231M | |||||
D&A | 19.78M | 21.72M | 19.71M | 19.97M | 21.26M | |||||
Operating Income | 109M | 81.88M | 209M | 332M | 228M | |||||
Net Income | 90.46M | 64.45M | 158M | 242M | 164M |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of World | 487M | 472M | 462M | 666M | 586M | |||||
Ethiopia | 95.76M | 32.23M | 158M | 247M | 164M | |||||
India | 149M | 275M | 200M | 219M | 94.46M | |||||
Total Assets | 591M | 508M | 518M | 529M | 637M | |||||
Export | - | - | - | - | - |
- Stock Market
- Stocks
- CORALAB6 Stock
- Financials Coral Laboratories Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
